Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Novartis AG (NVS) - free report >>
Merck & Co., Inc. (MRK) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - free report >>
Merck & Co., Inc. (MRK) - free report >>
Image: Bigstock
Ligand's Captisol Deals Set to Drive Growth in the Long Run
On Sep 26, 2017, we issued an updated report on Ligand Pharmaceuticals Incorporated (LGND - Free Report) .
Ligand’s leading Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG (NVS - Free Report) , Merck & Co., Inc. (MRK - Free Report) and Amgen Inc. (AMGN - Free Report) , thus in turn providing it with funds in the form of milestone and royalty payments.
Ligand receives royalties and milestone payments for several FDA-approved products that use its Captisol technology. Ligand’s major royalty revenues comes from sales of two key partnered assets — Novartis’ Kyprolis and Amgen’s Promacta. other latest product approvals include Spectrum’s Evomela, Lundbeck’s Carnexiv and Melinta Therapeutics’ Baxdela. Apart from these, several candidates are in late-stage development and expected to bring in royalties to the company once commercialized.
Regarding the company’s internal pipeline, various candidates are under observation and development for indications like diabetes. One such extremely advanced candidate is LGD-6972, presently undergoing a phase II study for treating type II diabetes. This month, the company reported positive top-line results from the study. It further expects LGD-6972 to bring in future licensing opportunities.
Nonetheless, Ligand’s entry into the Medical Devices Segment with acquisition of multiple programs owned by CorMatrix is also encouraging.
However, Ligand obtains Captisol from a single supplier, Hovione — a major global supplier of active pharmaceutical ingredients and drug product intermediates, located in Portugal. Any interruption in Captisol’s supply would hit the company’s results.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>